Biotechnology

Wednesday Apr 14, 2021 - 1:01 pm

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Colleague Receives 2021 International Dupuytren Award

180 Life Sciences Corp. (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has announced that Dr. Lynn Williams, PhD, has received the International Dupuytren Award 2021 for Basic Research. Williams’s research is sponsored by 180 Life Sciences. The award was given for research conducted by and a paper written by…

Wednesday Apr 14, 2021 - 12:49 pm

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Appoints Widely Acclaimed Leader as New Medical Director of Clinical Education

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), today announced the appointment of Mimi Guarneri, MD, FACC as an independent consultant serving in the role of medical director of Clinical Education, effective April 1, 2021. Dr. Guarneri is widely acclaimed as a leading Integrative cardiologist in…

Wednesday Apr 14, 2021 - 10:56 am

InvestorNewsBreaks – LexaGene Holdings Inc. (TSX.V: LXG) (OTCQB: LXXGF) to Host Private Seminar to Present MiQLab Data from Recent Study

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, announced that it will host a private event featuring Dr. Shelley Rankin, a professor of microbiology at the University of Pennsylvania’s School of Veterinary Medicine (Penn Vet). Attended by a select group of veterinarians, the private seminar will feature data compiled by Rankin based on her studies evaluating…

Tuesday Apr 13, 2021 - 2:31 pm

InvestorNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Enters Agreement for Upcoming Phase 1b/2a Clinical Trial

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, nonsystemic therapies for gastrointestinal (“GI”) diseases, has entered into an agreement with PPD Inc. (NASDAQ: PPD) for its upcoming phase 1b/2a clinical trial. PPD, a leading global contract research organization will manage the clinical trial using both oral immediate-release tablet and topical rectal enema foam formulations of micronized oral niclosamide, or FW-420 (“CRO”). The…

Friday Apr 09, 2021 - 11:58 am

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Eyes Expansion of AI-Driven Clinical Models

Predictive Oncology (NASDAQ: POAI) has set sights on other cancers after completing its data generation milestones in a collaborative study with UPMC-Magee Women Hospital. With the comprehensive genomic and transcriptomic sequencing of patient samples now complete, thanks to the study, and patient outcome data having been obtained from UPMC-Magee, “these data will now be used to drive POAI’s AI models of ovarian cancer and their…

Thursday Apr 08, 2021 - 2:20 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin to Demonstrate Effectiveness vs. Established Chemotherapy Drug in Phase 2 Trial

CNS Pharmaceuticals (NASDAQ: CNSP) continues to aggressively pursue FDA approval for its lead drug candidate, Berubicin. The novel candidate is the first anthracycline that appears to be able to cross the blood-brain barrier to combat tumors — stepping up its cancer-fighting potential. Berubicin was the subject of a Phase 1 safety trial conducted by Reata Pharmaceuticals approximately 15 years ago. One of the trial participants…

Thursday Apr 08, 2021 - 1:48 pm

InvestorNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Creates Win-Win Solution for Hospitals, Patients

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, has developed a solution set to lower the cost of treating bladder cancer and also help hospitals save money. As a result, Imagin will create a win-win situation for every party involved. The i/Blue(TM) Imaging System, Imagin’s proprietary solution, achieves this in two ways. “By displaying the blue light image that shows the highlighted cancer…

Wednesday Apr 07, 2021 - 1:08 pm

InvestorNewsBreaks – Healthy Extracts Inc. (HYEX) Shares Promising Clinical Study Results for HERHEART(TM), Fuel4Thought(TM) Brain Booster

Healthy Extracts (OTCQB: HYEX) is engaged in proprietary research and development of natural plant-based formulations, sales, and distribution of cardiovascular and neuro products. HYEX recently announced promising clinical study results for two of its subsidiary companies’ leading products: BergaMet North America’s HERHEART(TM) and Ultimate Brain Nutrients’ Fuel4Thought(TM) Brain Booster. “HERHEART(TM) is an exclusive natural supplement that is scientifically formulated specifically for women to support cardiovascular…

Monday Apr 05, 2021 - 1:49 pm

InvestorNewsBreaks – United Medical Equipment Business Solutions Network Inc. Poised Amid Demand for Rapid Testing Kits

United Medical Equipment (“UME,” “UMEBSNI”), a company offering rapid COVID-19 testing kits, looks positioned to benefit from the high demand for its products. The demand arises from expert recommendations that identifying those infected through rapid testing could help curb the virus and prevent the emergence of new variants. An article about these developments reads, “‘Testing is actually more important now than it was eight months…

Thursday Apr 01, 2021 - 10:33 am

InvestorNewsBreaks – LexaGene Holdings Inc. (TSX.V: LXG) (OTCQB: LXXGF) Reports Update in Shareholder Letter

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, has provided a corporate update in a shareholder letter from LexaGene CEO and founder Dr. Jack Regan. In the letter, Regan reported that the company had crossed a major milestone by securing a sales contract in both the drug and vaccine manufacturing market and in the veterinary medicine…

Tuesday Mar 30, 2021 - 2:34 pm

InvestorNewsBreaks – BioSig Technologies Inc. (NASDAQ: BSGM) Awarded U.S. Patent Claims for PURE EP(TM) Noise-Filtering Technology

BioSig Technologies (NASDAQ: BSGM), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the U.S. Patent Office had allowed a utility patent covering its PURE EP(TM) noise-filtering technology. According to the update, the recently allowed patent application number 17/082,564, entitled, “SYSTEMS AND METHODS FOR PERFORMING ELECTROPHYSIOLOGY…

Tuesday Mar 30, 2021 - 12:25 pm

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Preclinical Data Highlighting Potential for TUSC2 Immunogene Therapy to Be Featured at AACR 21

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that preclinical data of its TUSC2 immunogene therapy (REQORSA(TM)) in combination with chemotherapy and immunotherapies, as well as in combination with targeted therapies to overcome resistance to osimertinib, for the treatment of non-small cell lung cancer (“NSCLC”), will be featured in two presentations at…

Tuesday Mar 30, 2021 - 11:45 am

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Unveils New MyoCorrect Orofacial Myofunctional Therapy Service

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”), has announced a new service called MyoCorrect. The exclusive training provides therapists with access to orofacial myofunctional therapy (“OMT”) via telemedicine technology using the company’s Vivos System. Vivos anticipates this new service will provide increased revenue through With this new training,…

Tuesday Mar 30, 2021 - 11:04 am

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Leverages Multi-Omic Approach to New Drug Discovery

Predictive Oncology (NASDAQ: POAI) is a knowledge-driven company focused on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery. While the pharmaceutical industry has historically invested heavily in genomics and big data, hoping to better understand individual patient’s genomes and deliver targeted therapeutics, the use of genomics alone has proven disappointing. Predictive Oncology is confident that a multi-omic approach offers a…

Monday Mar 29, 2021 - 1:35 pm

InvestorNewsBreaks – United Medical Equipment Business Solutions Network Inc. Featured in Latest Episode of Bell2Bell Podcast

United Medical Equipment (“UME,” “UMEBSNI”) was featured in the The Bell2Bell Podcast, a part of InvestorBrandNetwork’s (“IBN”) sustained effort to provide specialized content distribution via widespread syndication channels. UME’s President, Jason Pratt, and VP of Sales, Brian Gartland, joined the latest episode to discuss United Medical Equipment’s trusted-provider business model. “Every day, 10,000 people turn 65 in the United States. Having a home health background,…

Monday Mar 29, 2021 - 1:11 pm

InvestorNewsBreaks – Brain Scientific Inc. (BRSF) Bringing Cost-Effective, Compact Solutions to Emergency Medicine

Brain Scientific (OTCQB: BRSF), with its low-cost, portable, wireless and easy-to-use electroencephalogram (“EEG”) devices, the NeuroCap(TM) and NeuroEEG(TM), has overcome the barriers preventing the use of EEGs in emergency settings. This means that patients and emergency departments can more readily realize numerous EEG benefits. An EEG can make the distinction between dementia and delirium, adequately determine the severity of a mild traumatic brain injury (“mTBI”),…

Monday Mar 29, 2021 - 11:53 am

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Featured in NetworkNewsAudio Broadcast

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, this morning announced that it was featured in a NetworkNewsAudio production highlighting the company’s recent news that it has received European approval for its SARS-CoV-2 (COVID-19) RT-PCR test system (Covid-ID Lab). “Our test is one of the fastest PCR-based COVID-19 tests…

Friday Mar 26, 2021 - 12:13 pm

InvestorNewsBreaks – Imagin Medical Inc.’s (CSE: IME) (OTCQB: IMEXF) Breakthrough Technology Rectifies Cystoscopy Limitations

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, has developed proprietary technology that solves the issues associated with existing cystoscopies. “White light images show the full landscape of the bladder but do not effectively highlight cancer,” reads an article about the benefits of the i/Blue Imaging(TM) System, Imagin Medical’s proprietary technology. “A promising new modality, blue light cystoscopy, uses blue-filtered white light to…

Friday Mar 26, 2021 - 10:00 am

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases FY 2020 Financial, Corporate Report

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and quality of life for patients who have unmet medical needs, has reported its financial numbers for the year ending Dec. 31, 2020; the company also reported a corporate update. High on the list of noteworthy achievements for the year 2020 was the selection of five U.S. clinical sites for the…

Friday Mar 26, 2021 - 9:26 am

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q4, FY 2020 Financial, Operational Results

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”), reported is financial and operational results for the fourth quarter and fiscal year ending Dec. 31, 2020. The company also held a conference call on March 25, 2021, to discuss the new report. High on the list of significant…

Thursday Mar 25, 2021 - 1:29 pm

InvestorNewsBreaks – Kaival Brands Innovations Group Inc. (KAVL), Bidi Welcome Category Reform in China

Kaival Brands Innovations Group (KAVL), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, has noted recent news from China outlining increased supervision over the e-cigarette category. KAVL, which is the exclusive global distributor of all products manufactured by Bidi Vapor LLC, welcomes the news, particularly as it pertains the BIDI(R) Stick disposable electronic nicotine delivery system (“ENDS”). The company…

Thursday Mar 25, 2021 - 1:14 pm

InvestorNewsBreaks – Healthy Extracts Inc. (HYEX) Achieves Strong Growth Amid Booming Market

Healthy Extracts (OTCQB: HYEX), a leading developer and manufacturer of heart health, brain health and supplementary technologies, reported a revenue increase of 71% from $748,377 in 2019 to $1,276,559 over the 12 months ending December 31, 2020. The company attributes this growth to the transition to its new business selling health nutrition products, which positions HYEX for opportunity in the booming plant-based foods and products…

Wednesday Mar 24, 2021 - 1:17 pm

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Working to Expand Test Portfolio

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), which recently received European approval for its COVID-19 rapid and portable test system, has set out to increase its portfolio of tests for different diseases to help fight the current and potential pandemics. XPhyto has partnered with Germany’s 3a-diagnostics GmbH for this, according to an article on the company’s recent announcements. “The company is also working with…

Wednesday Mar 24, 2021 - 12:58 pm

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Spring 2021 Oncology Investor Conference

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that it will present at the Spring 2021 Oncology Investor Conference taking place virtually March 29 - April 2, 2021. According to the update, Genprex’s president and CEO, Rodney Varner, will deliver a virtual company overview that includes GNPX’s novel gene therapies for non-small…

Tuesday Mar 23, 2021 - 11:21 am

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Present at Benzinga Biotech Conference

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), has announced that it will participate at the Benzinga Biotech Small Cap Conference taking place from March 24-25, 2021. Vivos Chief Executive Officer, Kirk Huntsman, Chief Financial Officer, Brad Amman, and Investor Relations Officer, Ed Loew, will be…

Tuesday Mar 23, 2021 - 11:00 am

InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Appoints Board Chair as New CEO

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announce the appointment of a new CEO: J. Melville (“Mel”) Engle. Engle is currently serving as chairman of the board and will continue to serve in that role as well as in his new position as CEO. Engle has more than two decades of impressive experience…

Monday Mar 22, 2021 - 10:08 am

InvestorNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Completes Enrollment in Phase 2 MS1819-PERT Combination Clinical Trial

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today announced completion of enrollment in its Phase 2 trial evaluating MS1819 in combination with the current standard of care, porcine-derived pancreatic enzyme replacement therapy (“PERT”). The combination trial is for the treatment of severe exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis (“CF”).…

Friday Mar 19, 2021 - 3:37 pm

InvestorNewsBreaks – RYAH Group Inc. Provides Digital Approach to Positively Impact Future Medical Treatments

RYAH Group, a leading digital health care analytics and technology company, has developed a technology that collects and analyzes patient data, creating an anonymous database that, when coupled with AI, will guide the future of medical treatments. With the technology, “patients can set usage limits, track usage in real time, record how they feel after sessions and review stats over time,” reads an article on…

Friday Mar 19, 2021 - 11:59 am

InvestorNewsBreaks – Bio-Path Holdings Inc. (NASDAQ: BPTH) Secures $13M in Public Offering

Bio-Path Holdings (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize(R) liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, has closed a public offering of 1,710,600 shares of common stock. Bio-Path Holdings secured approximately $13 million in gross proceeds, with each of the shares sold at the public offering price of $7.60. Bio-Path intends to use the proceeds…

Wednesday Mar 17, 2021 - 1:24 pm

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Sites for Phase 2B Clinical Trial

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or quality of life, today announced that it has selected five U.S. clinical sites to enroll patients with ulcerative necrobiosis lipoidica for the company’s Phase 2B trial. In addition, two to three more clinical sites will be selected…

Wednesday Mar 17, 2021 - 9:33 am

InvestorNewsBreaks – Brain Scientific Inc. (BRSF) Enters Strategic Collaboration with JelikaLite

Brain Scientific (OTCQB: BRSF), a neurology focused medical device and software company, recently announced a collaboration with JelikaLite, a company developing Cognilum(TM), a non-invasive wearable photobiomodulation device that is being developed to increase the well-being of children living with autism, through a clinical trial. In the trial, “Transcranial Photobiomodulation for Reducing Autism Symptoms in Children,” brain treatments for children diagnosed with autism would be delivered…

Tuesday Mar 16, 2021 - 1:38 pm

InvestorNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Completes Enrollment in Upcoming Phase 2b Clinical Trial of Cystic Fibrosis Treatment

AzurRx BioPharma (NASDAQ: AZRX), a clinical-stage biopharmaceutical company specializing in the development of targeted, nonsystemic therapies for gastrointestinal (“GI”) diseases, has announced the completion of enrollment for its phase 2b OPTION 2 clinical trial to investigate MS1819 in cystic fibrosis (“CF”) patients with exocrine pancreatic insufficiency (“EPI”). According to the announcement, the company enrolled 30 CF patients for the study, which is anticipated to return…

Tuesday Mar 16, 2021 - 12:46 pm

InvestorNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Announces Continued Manufacturing Progress

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures, today announced continued progress towards commercial-stage manufacturing capability with Lighthouse Imaging. Prior to selection of Lighthouse as its contract manufacturer for the i/Blue Imaging System(TM) in October 2020, Imagin received multiple fully functional feasibility units from its original design partner,…

Tuesday Mar 16, 2021 - 12:21 pm

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation Schedule for Upcoming March Investor Conferences

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced that its Chief Executive Officer, Shawn Singh, will participate in two investor conferences in March. For the Maxim Group and M-Vest’s Inaugural Emerging Growth Virtual Conference taking place on March 17-19, 2021,…

Tuesday Mar 16, 2021 - 9:48 am

InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Releases FY 2020 Financial Results, Business Highlights

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has reported business highlights and financial results for the year ended Dec. 31, 2020. Highlights discussed in the report include the company’s reinforced balance sheet with net debt and equity offerings for estimated net proceeds of $12,952,689; completion of an asset purchase agreement to acquire Soluble…

Thursday Mar 11, 2021 - 11:29 am

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Leaders to Present at Upcoming Virtual Investor Summit

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”) has announced that CEO Kirk Huntsman, CFO Brad Amman and investor relations officer Ed Loew are scheduled to present at the Q1 Virtual Investor Summit. Vivos Therapeutics’ presentation is scheduled for 1:30 p.m. ET on March 23, 2021. The…

Wednesday Mar 10, 2021 - 9:59 am

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announced Partner Has Received ISO Certification for Rapid COVID-19 Test

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, has announced that 3a-diagnostics GmbH ("3a") has received EN ISO 13485 certification for its rapid point-of-care, SARS-CoV-2 RT-PCR Test System ("Covid-ID Lab"). 3a-diagnostics is XPhyto’s exclusive German diagnostics development partner. In addition the company expects CE-IVD approval for the product this month. These…

Wednesday Mar 10, 2021 - 9:02 am

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces FDA 510(k) Application for Exclusive Oral Appliance

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”), recently submitted an application to the U.S. Food and Drug Administration (“FDA”) for its mmRNA (“mmRNA”) oral appliance(TM). The 510(k) Class II application focuses on the oral appliance as a treatment for mild-to-moderate OSA, sleep-disordered breathing and snoring in…

Tuesday Mar 09, 2021 - 12:46 pm

InvestorNewsBreaks – Healthy Extracts Inc. (HYEX) Releases FY 2020 Revenue Results, Year-End Accomplishments

Healthy Extracts (OTCQB: HYEX), a leading developer and manufacturer of heart health, brain health and supplementary technologies, has announced its year-end financial numbers and business updates for the 12-month period ending Dec. 31, 2020. Financial highlights of the report include revenue increases of 71% to $1,276,559 compared to 2019 revenues of $748,377 and a net shareholder equity increase of $3.7 million. In addition, the company eliminated…

Tuesday Mar 09, 2021 - 11:53 am

InvestorNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Reports Q4, FY 2020 Numbers, Business Highlights

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, has released its financial and business update report for the fourth quarter and full year 2020. The company reports significant progress across all aspects of its long-term strategic operating plan, including securing several accounts in the B2B (“B2B”) channel that are generating revenue and enrolling members and completing financing that provides capital to move…

InvestorNewsBreaks

NewsBreak Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions